Quest for the right Drug
מוקסיפן ® פורטה 250 מ"ג אבקה להרחפה MOXYPEN ® FORTE 250 MG POWDER FOR SUSPENSION (AMOXICILLIN AS TRIHYDRATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
אבקה להכנת תרחיף : POWDER FOR ORAL SUSPENSION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
8 ADVERSE REACTIONS 8.1 Adverse Reaction Overview As with other penicillins, it may be expected that untoward reactions will be related to sensitivity phenomena. They are more likely to occur in individuals who have previously demonstrated hypersensitivity to penicillins and cephalosporins and in those with a history of allergy, asthma, hay fever or urticaria. 8.2 Clinical Trial Adverse Reactions The following adverse reactions have been reported as associated with the use of Moxypen Forte: Gastrointestinal ‐ Nausea, vomiting and diarrhea, hemorrhagic and pseudomembranous colitis. Clostridium difficile‐associated disease (CDAD) has been reported with use of many antibacterial agents, including amoxicillin. Glossitis, black "hairy" tongue and stomatitis, mucocutaneous candidiasis, tooth discoloration (brown, yellow or gray staining); most reports occurred in pediatric patients. Discoloration was reduced or eliminated with brushing or dental cleaning in most cases. Hypersensitivity Reactions ‐ Skin rashes have been reported frequently. Less commonly, a few cases of serum sickness like reactions including urticaria, erythema, erythema multiforme, angioneurotic edema, pruritus have been reported. Rarely, Stevens‐Johnson syndrome, toxic epidermal necrolysis, bullous dermatitis, exfoliative dermatitis, acute generalized exanthematous pustulosis, hypersensitivity vasculitis have been reported. Anaphylaxis is the most serious reaction experienced and has usually been associated with the parenteral dosage form. NOTE: Urticaria, other skin rashes, and serum sickness‐like reactions may be controlled with antihistamines and if necessary, systemic corticosteroids. Whenever such reactions occur, Moxypen Forte (amoxicillin) should be discontinued unless, in the opinion of the physician, the condition being treated is life threatening and amenable only to amoxicillin therapy. Serious anaphylactic reactions require the immediate use of epinephrine, oxygen and intravenous steroids. Hepatobiliary ‐ A moderate rise in serum glutamic oxaloacetic transaminase (SGOT) has been noted, particularly in infants, but the significance of this finding is not known. Transient increases in serum alkaline phosphatase and lactic dehydrogenase levels have also been observed but they returned to normal on discontinuation of amoxicillin. Reports have also been seen of hepatic dysfunction including cholestatic jaundice, hepatic cholestasis, acute cytolytic hepatitis, Hemic and Lymphatic Systems ‐ Anemia thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, neutropenia and agranulocytosis have been reported during therapy with the penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be a hypersensitivity phenomena. Reports have also been seen of anemia including hemolytic anemia. Central Nervous System ‐ As with other penicillins, acute and chronic toxicity is not a clinical problem. Although penicillins do not normally cross the blood‐brain barrier to any substantial extent, if massive doses are given (several grams per day) to elderly patients, patients with inflamed meninges or patients with impaired renal function, toxic reactions are likely to occur. At extremely high doses, convulsions can occur. When penicillin reaches a high concentration in the cerebrospinal fluid, neurotoxic symptoms consisting of myoclonia, convulsive seizures and depressed consciousness may occur. Unless administration of the drug is stopped or its dosage reduced, the syndrome may progress to coma and death. Dizziness, hyperkinesias, hyperactivity, agitation, anxiety, insomnia, confusion, and behavioural changes have also been reported. Skin and Appendages ‐ erythematous maculopapular rash. Renal ‐ Crystalluria. Interstitial nephritis (oliguria, proteinuria, hematuria, hyaline casts, pyuria) and nephropathy are infrequent and usually associated with high doses of parenteral penicillins; however, this has occurred with all of the penicillins. Such reactions are hypersensitivity responses and are usually associated with fever, skin rash and eosinophilia. Elevations of creatinine or blood urea nitrogen may occur. 8.3 Post‐Marketing Adverse Reactions Central Nervous System: Amoxicillin can lead to cases of aseptic meningitis of unknown frequency. Other immune system disorders: Kounis syndrome 8.4 Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: https://sideeffects.health.gov.il
שימוש לפי פנקס קופ''ח כללית 1994
respiratory infections (otitis, sinusitis, bronchitis & pneumonia) gastrointestinal infections, genitourinary tract infections, gonorrhea, soft tissue infections caused by: streptococci, pneumococci, staphylococci, enterococci, H. influenzae, E. coli, proteus, gonococci, shigella, salmonella. prophylaxis of endocarditis.
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף
עלון מידע לצרכן
04.01.22 - עלון לצרכן אנגלית 04.01.22 - עלון לצרכן עברית 04.01.22 - עלון לצרכן ערבית 21.08.23 - עלון לצרכן עברית 28.12.23 - עלון לצרכן עברית 01.02.24 - עלון לצרכן אנגלית 01.02.24 - עלון לצרכן עברית 01.02.24 - עלון לצרכן ערבית 09.03.14 - החמרה לעלון 06.10.21 - החמרה לעלון 18.10.21 - החמרה לעלון 03.01.22 - החמרה לעלון 21.08.23 - החמרה לעלון 05.02.24 - החמרה לעלוןלתרופה במאגר משרד הבריאות
מוקסיפן ® פורטה 250 מ"ג אבקה להרחפה